ERX 208
Alternative Names: ERX-208Latest Information Update: 09 Jun 2022
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer EtiraRx
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Ovarian cancer
Most Recent Events
- 09 Jun 2022 ERX 208 is available for licensing as of 09 Jun 2022. https://www.etirarx.com/mission-vision/
- 09 Jun 2022 Preclinical trials in Ovarian cancer in USA (unspecified route) before June 2022 (EtiraRx pipeline, June 2022)
- 03 Jun 2022 EtiraRx in-licenses ERX 41 and the related portfolio from University of Texas Southwestern Medical Center